Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study-Reference-Cited by-全球学者库

Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study

Published:2021-12 Issue:12 Volume:16 Page:2109-2120
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Yang Yunpeng,Sun Jiya,Wang Zhehai,Fang Jian,Yu Qitao,Han Baohui,Cang Shundong,Chen Gongyan,Mei Xiaodong,Yang Zhixiong,Ma Rui,Bi Minghong,Ren Xiubao,Zhou Jianying,Li Baolan,Song Yong,Feng Jifeng,Li Juan,He Zhiyong,Zhou Rui,Li Weimin,Lu You,Zhou Hui,Wang Shuyan,Sun Luyao,Puig Oscar,Mancao Christoph,Peng Bo,Fang Wenfeng,Xu Wei,Zhang Li

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference29 articles.

1. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer;Gandhi;N Engl J Med,2018

2. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer;Paz-Ares;N Engl J Med,2018

3. Evaluation of TMB in KEYNOTE-189: pembrolizumab plus chemotherapy vs placebo plus chemotherapy for nonsquamous NSCLC;Garassino;J Thorac Oncol,2019

4. LBA80 Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407;Paz-Ares;Ann Oncol,2019

5. Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial;Shi;Lancet Haematol,2019

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical benefit of anti-PD-1/PD-L1 plus chemotherapy in first-line treatment for patients over the age of 65 or 75 with metastatic non-small cell lung cancer (NSCLC);Journal of Chemotherapy;2024-02

2. Advances and challenges of first-line immunotherapy for non-small cell lung cancer: A review;Medicine;2024-01-19

3. Class II HLA-DRB4 is a predictive biomarker for survival following immunotherapy in metastatic non-small cell lung cancer;Scientific Reports;2024-01-03

4. First-line therapy;Lung Cancer;2024

5. Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial;ESMO Open;2023-12